Relapse/Refractory Mantle Cell Lymphoma
1 clinical trials · Condition
◉ Watch Relapse/Refractory Mantle Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies (NCT04162756) | Kite, A Gilead Company |
Track Relapse/Refractory Mantle Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.